NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Evaxion A/S (EVAX) Stock Analysis

Evaxion A/S (EVAX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

EVAX

$3.71

−$0.34 (−8.40%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EVAX with… →

EVAX Key Statistics

As of Oct 21, 2026
Trading
Open
$4.16
Previous Close
$4.05
Day's Range
3.65–4.50
52-Week Range
2.72–6.92
Volume
325.35K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.51
Valuation
Market Cap
$33.47M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.47
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.00
Financials (FY)
Revenue (FY)
$7.53M+125.12%
Net Income (FY)
−$7.71M
Profit marginThe share of revenue left as profit after all costs and taxes.
−115.54%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
9.02M
1-Year Return
−43.19%
Dividend and dates
Avg Volume
219.84K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, EVAX closed at $3.71, −43.19% over 1 year.

Evaxion A/S (EVAX) has a market capitalization of $33.47M.

In fiscal 2025, EVAX reported revenue of $7.53M.

EVAX Stock Return by Calendar Year

Evaxion A/S (EVAX) return since Feb 2021: what $10,000 became

1 year
$10,000 $5,681
−43.19%
5 years
$10,000 $93
−99.07%
Since Feb 2021
$10,000 $75
−99.25%

If you had invested $10,000 in Evaxion A/S (EVAX) at the close on February 5, 2021, the earliest close on record here, it would have been worth $75 at the close on October 21, 2026: −99.25% in total, −57.58% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−22.22%
2025+12.90%
2024−87.68%
2023−61.35%
2022−59.84%
2021 (partial year)−55.31%

As of October 21, 2026.

EVAX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$7.53M−$7.71M−102.4%
2024$3.34M−$10.57M−316.0%
2023$73.00K−$22.13M−30,308.2%
2022$0.00−$23.17M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.53M—−$9.23M−$7.71M−102.4%
2024$3.34M—−$14.73M−$10.57M−316.0%
2023$73.00K—−$22.20M−$22.13M−30,308.2%
2022$0.00—−$25.26M−$23.17M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

EVAX Valuation vs Biotechnology Median

Median of 608 stocks
MetricEVAXBiotechnology medianvs median
P/S ratio4.4713.3066% below
Profit margin−115.54%−38.31%77.2 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Evaxion A/S (EVAX) carries a market capitalisation of $33.47M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 46.

EVAX last closed at $3.71 on October 21, 2026. That is −$0.34 (−8.40%) against the previous close. Over the past 52 weeks the price has ranged from $2.72 to $6.92. The latest close sits 36.4% above that 52-week low.

Financial Health

In fiscal 2025, Evaxion A/S reported revenue of $7.53M. That is +125.12% against the prior fiscal year, when revenue was $3.34M. The same year closed with a net loss of $7.71M. The reported profit margin is −115.54%. That is 77.2 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −1.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $7.53M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 4.47. On price-to-sales that is 66.4% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.51. Daily returns over the trailing 5 years annualize to a volatility of 130.09%. Over the trailing twelve months the total return is −43.19%. Across 5 years the annualized return works out at −60.77%.

Growth & Income

No dividend is on file for EVAX.

So far in 2026 the total return is −22.22%. The strongest complete calendar year on file is 2025 at +12.90%; the weakest is 2024 at −87.68%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Evaxion A/S (EVAX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Evaxion A/S EVAX $33.47M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Evaxion A/S has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Evaxion A/S

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Visit website →